Notice
3 Feb 2025
compliance, fda, regulatory requirements, user fees, healthcare industry, biosimilars
💊FDA Biosimilars User Fee Program
The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Learn More